NLRP3 and COVID-19: As a candidate for potential use in COVID-19, rapamycin may prevent progression to severe forms of COVID-19 by downregulating the IL-6 pathway and reducing the number of senescent T-cells through the mTOR-NLRP3-IL-1β axis at the early stage of cytokine storms [111, 112].